EPS for Cambrex Corporation (CBM) Expected At $0.59

October 13, 2018 - By Nellie Frank

Investors sentiment increased to 1.51 in Q2 2018. Its up 0.32, from 1.19 in 2018Q1. It is positive, as 31 investors sold Cambrex Corporation shares while 51 reduced holdings. 37 funds opened positions while 87 raised stakes. 32.93 million shares or 1.56% more from 32.42 million shares in 2018Q1 were reported.
Mark Sheptoff Planning Lc holds 0.15% or 3,900 shares in its portfolio. Alps Advsr Incorporated invested 0% in Cambrex Corporation (NYSE:CBM). Comerica Bank & Trust holds 0.02% in Cambrex Corporation (NYSE:CBM) or 40,263 shares. Credit Suisse Ag reported 38,452 shares. Fifth Third National Bank reported 539 shares stake. Granite Invest Limited Liability holds 0.97% of its portfolio in Cambrex Corporation (NYSE:CBM) for 291,775 shares. New York-based Quantbot Technologies L P has invested 0.15% in Cambrex Corporation (NYSE:CBM). 4,131 are owned by Da Davidson &. Gsa Capital Ltd Liability Partnership invested 0.04% in Cambrex Corporation (NYSE:CBM). Glenmede Na invested in 344 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 2,080 shares. 618,009 were accumulated by Lazard Asset Mngmt Limited Liability Company. Metropolitan Life has invested 0% in Cambrex Corporation (NYSE:CBM). 464,112 are held by Investment Counselors Of Maryland Limited Liability Corporation. Mutual Of America Cap Management Ltd Liability Com accumulated 25,610 shares.

Since May 7, 2018, it had 0 insider buys, and 6 sales for $14.93 million activity. Vadaketh Tom George sold $603,098 worth of stock or 9,510 shares. SARGEN GREGORY sold $3.34 million worth of stock or 67,500 shares. 40,000 Cambrex Corporation (NYSE:CBM) shares with value of $1.99M were sold by Cavanagh Shawn.

Analysts expect Cambrex Corporation (NYSE:CBM) to report $0.59 EPS on November, 6.They anticipate $0.04 EPS change or 7.27 % from last quarter’s $0.55 EPS. CBM’s profit would be $19.62 million giving it 25.52 P/E if the $0.59 EPS is correct. After having $1.21 EPS previously, Cambrex Corporation’s analysts see -51.24 % EPS growth. The stock increased 0.58% or $0.35 during the last trading session, reaching $60.23. About 266,603 shares traded. Cambrex Corporation (NYSE:CBM) has risen 30.46% since October 13, 2017 and is uptrending. It has outperformed by 14.84% the S&P500.

Cambrex Corporation, a life sciences company, provides various services and products for the development and commercialization of new and generic therapeutics worldwide. The company has market cap of $2.00 billion. The company??s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. It has a 16.54 P/E ratio. It serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics.

Another recent and important Cambrex Corporation (NYSE:CBM) news was published by Globenewswire.com which published an article titled: “Market Trends Toward New Normal in Ellington Financial, InfraREIT, Itron, KAR Auction Services, Cambrex, and …” on October 08, 2018.

Cambrex Corporation (NYSE:CBM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.